Education
About Us
Working with TipRanks
Follow Us
Titan Pharmaceuticals (TTNP)
NASDAQ:TTNP
RESEARCH TOOLSreports
Total Valuation
Titan Pharmaceuticals has a market cap or net worth of $3.34M. The enterprise value is ―.
Market Cap$3.34M
Enterprise Value―
Share Statistics
Titan Pharmaceuticals has 914,234 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding914,234
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Titan Pharmaceuticals’s return on equity (ROE) is -1.93 and return on invested capital (ROIC) is -186.76%.
Return on Equity (ROE)-1.93
Return on Assets (ROA)-1.61
Return on Invested Capital (ROIC)-186.76%
Return on Capital Employed (ROCE)-1.87
Revenue Per Employee0.00
Profits Per Employee-1.18M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Titan Pharmaceuticals is -0.62. Titan Pharmaceuticals’s PEG ratio is 0.02.
PE Ratio-0.62
PS Ratio3830.64
PB Ratio1.20
Price to Fair Value1.20
Price to FCF-0.76
Price to Operating Cash Flow-0.76
PEG Ratio0.02
Income Statement
In the last 12 months, Titan Pharmaceuticals had revenue of 0.00 and earned -4.71M in profits. Earnings per share was -5.23.
Revenue0.00
Gross Profit0.00
Operating Income-4.56M
Pretax Income-4.71M
Net Income-4.71M
EBITDA-4.56M
Earnings Per Share (EPS)-5.23
Cash Flow
In the last 12 months, operating cash flow was -3.88M and capital expenditures 0.00, giving a free cash flow of -3.88M billion.
Operating Cash Flow-3.88M
Free Cash Flow-3.88M
Free Cash Flow per Share-4.24
Dividends & Yields
Titan Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.03
52-Week Price Change-46.92%
50-Day Moving Average3.75
200-Day Moving Average4.41
Relative Strength Index (RSI)49.69
Average Volume (3m)24.49K
Important Dates
Titan Pharmaceuticals upcoming earnings date is Nov 11, 2024, TBA Not Confirmed.
Last Earnings DateNov 13, 2023
Next Earnings DateNov 11, 2024
Ex-Dividend Date―
Financial Position
Titan Pharmaceuticals as a current ratio of 6.05, with Debt / Equity ratio of 0.00%
Current Ratio6.05
Quick Ratio6.05
Debt to Market Cap0.00
Net Debt to EBITDA0.62
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Titan Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Titan Pharmaceuticals EV to EBITDA ratio is -0.02, with an EV/FCF ratio of -0.03.
EV to Sales0.00
EV to EBITDA-0.02
EV to Free Cash Flow-0.03
EV to Operating Cash Flow-0.03
Balance Sheet
Titan Pharmaceuticals has $2.83M in cash and marketable securities with $33.00K in debt, giving a net cash position of -$2.83M billion.
Cash & Marketable Securities$2.83M
Total Debt$33.00K
Net Cash-$2.83M
Net Cash Per Share-$3.10
Tangible Book Value Per Share$2.71
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Titan Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast28.48%